Accelerating Next-Generation Vaccine Development for Global Disease Prevention

• Type of Material: Article
• Authors: Wayne C Koff, International AIDS Vaccine Initiative; Dennis R. Burton, Government of India; Philip R. Johnson, Childrens Hospital of Philadelphia; Bruce D. Walker, MIT and Harvard; Charles R. King, International AIDS Vaccine Initiative; Gary J. Nabel, Sanofi Aventis; Rafi Ahmed, Emory University; Maharaj Kishan Bhan, Government of India; Stanley A. Plotkin, University of Pennsylvania
• Language: English
• Date: 2013-05-31
• Publisher: American Association for the Advancement of Science
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: Copyright © 2013, American Association for the Advancement of Science
• Final Published Version (URL): http://dx.doi.org/10.1126/science.1232910
• Title of Journal or Parent Work: Science
• ISSN: 0036-8075
• Volume: 340
• Issue: 6136
• Start Page: 1232910
• End Page: 1232910
• Keywords: IMMUNOSTIMULATORY DNA; IMMUNODEFICIENCY-VIRUS TYPE-1; Multidisciplinary Sciences; REVERSE VACCINOLOGY; DENDRITIC CELLS; Science & Technology; MYCOBACTERIUM-TUBERCULOSIS; INNATE IMMUNITY; HIV-1 VACCINE; T-CELL RESPONSES; HUMAN IMMUNOLOGY; Science & Technology - Other Topics; NEUTRALIZING ANTIBODIES
• Research Categories: Health Sciences, Immunology; Health Sciences, Public Health; Health Sciences, Pharmacology

Abstract

Vaccines are among the greatest successes in the history of public health. However, past strategies for vaccine development are unlikely to succeed in the future against major global diseases such as AIDS, tuberculosis, and malaria. For such diseases, the correlates of protection are poorly defined and the pathogens evade immune detection and/or exhibit extensive genetic variability. Recent advances have heralded in a new era of vaccine discovery. However, translation of these advances into vaccines remains impeded by lack of understanding of key vaccinology principles in humans. We review these advances toward vaccine discovery and suggest that for accelerating successful vaccine development, new human immunology-based clinical research initiatives be implemented with the goal of elucidating and more effectively generating vaccine-induced protective immune responses.